268 related articles for article (PubMed ID: 27736267)
1. miRNAs in chronic myeloid leukemia: small molecules, essential function.
Litwińska Z; Machaliński B
Leuk Lymphoma; 2017 Jun; 58(6):1297-1305. PubMed ID: 27736267
[TBL] [Abstract][Full Text] [Related]
2. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
Ali MA
Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
[TBL] [Abstract][Full Text] [Related]
3. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
4. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.
Yang K; Fu LW
Crit Rev Oncol Hematol; 2015 Mar; 93(3):277-92. PubMed ID: 25500000
[TBL] [Abstract][Full Text] [Related]
6. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.
Patel AB; O'Hare T; Deininger MW
Hematol Oncol Clin North Am; 2017 Aug; 31(4):589-612. PubMed ID: 28673390
[TBL] [Abstract][Full Text] [Related]
8. Identification of key candidate targets and pathways for the targeted treatment of leukemia stem cells of chronic myelogenous leukemia using bioinformatics analysis.
Li H; Liu L; Zhuang J; Liu C; Zhou C; Yang J; Gao C; Liu G; Sun C
Mol Genet Genomic Med; 2019 Sep; 7(9):e851. PubMed ID: 31373443
[TBL] [Abstract][Full Text] [Related]
9. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
[TBL] [Abstract][Full Text] [Related]
10. Expression pattern of key microRNAs in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Fallah P; Amirizadeh N; Poopak B; Toogeh G; Arefian E; Kohram F; Hosseini Rad SM; Kohram M; Teimori Naghadeh H; Soleimani M
Int J Lab Hematol; 2015 Aug; 37(4):560-8. PubMed ID: 25833191
[TBL] [Abstract][Full Text] [Related]
11. Role of miRNAs to control the progression of Chronic Myeloid Leukemia by their expression levels.
Bansal M; Ansari S; Verma M
Med Oncol; 2024 Jan; 41(2):55. PubMed ID: 38216843
[TBL] [Abstract][Full Text] [Related]
12. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
13. miRNAs as Biomarkers in Chronic Myelogenous Leukemia.
Kotagama K; Chang Y; Mangone M
Drug Dev Res; 2015 Sep; 76(6):278-85. PubMed ID: 26284455
[TBL] [Abstract][Full Text] [Related]
14. Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML).
Desterke C; Voldoire M; Bonnet ML; Sorel N; Pagliaro S; Rahban H; Bennaceur-Griscelli A; Cayssials E; Chomel JC; Turhan AG
Exp Hematol; 2018 Aug; 64():71-83.e8. PubMed ID: 29733872
[TBL] [Abstract][Full Text] [Related]
15. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
16. Non-Coding RNAs Are Implicit in Chronic Myeloid Leukemia Therapy Resistance.
Rudich A; Garzon R; Dorrance A
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293127
[TBL] [Abstract][Full Text] [Related]
17. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.
Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G
Cancer Lett; 2015 May; 360(2):245-56. PubMed ID: 25697481
[TBL] [Abstract][Full Text] [Related]
18. The roles of microRNAs in the pathogenesis and drug resistance of chronic myelogenous leukemia (Review).
Di Stefano C; Mirone G; Perna S; Marfe G
Oncol Rep; 2016 Feb; 35(2):614-24. PubMed ID: 26718125
[TBL] [Abstract][Full Text] [Related]
19. Expression of Hippo signaling pathway and Aurora kinase genes in chronic myeloid leukemia.
Marsola APZC; Simões BP; Palma LC; Berzoti-Coelho MG; Burin SM; de Castro FA
Med Oncol; 2018 Jan; 35(3):26. PubMed ID: 29387948
[TBL] [Abstract][Full Text] [Related]
20. Role of anti-apoptotic pathways activated by BCR/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors.
Danisz K; Blasiak J
Acta Biochim Pol; 2013; 60(4):503-14. PubMed ID: 24273759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
